Insider · CIK 0001488486
Helen C. Adams
Files at IMMX (Immix Biopharma, Inc.). First filing -, latest -.
In brief
Helen C. Adams files SEC Form 4 as director at IMMX (Immix Biopharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Helen C. Adams has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | IMMX Immix Biopharma, Inc. | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 181,004 | May 29, 2026 |
| May 22, 2026 | IMMX Immix Biopharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 29, 2026 |
| Jun 20, 2025 | IMMX Immix Biopharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 23, 2025 |
Questions about Helen C. Adams
Answered from the filings on this page, as of the latest one.
Is Helen C. Adams buying or selling?
Helen C. Adams has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Helen C. Adams's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Helen C. Adams has 0.
Where does Helen C. Adams file Form 4?
Helen C. Adams has filed Form 4 at IMMX (Immix Biopharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.